- Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
- Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
- Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
Key statistics
On Tuesday, Propanc Biopharma Inc (PPCB:PKC) closed at 0.0014, 125.00% above the 52 week low of 0.0006 set on May 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0013 |
---|---|
High | 0.0017 |
Low | 0.0012 |
Bid | -- |
Offer | -- |
Previous close | 0.0011 |
Average volume | 55.35m |
---|---|
Shares outstanding | 167.98m |
Free float | 167.26m |
P/E (TTM) | -- |
Market cap | 184.78k USD |
EPS (TTM) | -0.3033 USD |
Data delayed at least 15 minutes, as of Jun 25 2024 20:51 BST.
More ▼